Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
SZLSF StageZero Life Sciences	$0.04	$0.03	$0.03 ▼ $0.06	$4.82M	0.61	70,986 shs	N/A
VRAX Virax Biolabs Group	$0.68 -1.4%	$0.83	$0.61 ▼ $8.54	$1.07M	0.96	81,360 shs	4,769 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
SZLSF StageZero Life Sciences	0.00%	+35.42%	+44.44%	+35.42%	-38.39%
VRAX Virax Biolabs Group	-1.19%	-12.86%	-16.14%	-33.36%	-87.86%

New crypto project uncovers 2,050% in 65 days (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
SZLSF StageZero Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
SZLSF StageZero Life Sciences	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
SZLSF StageZero Life Sciences	$3.80M	1.27	N/A	N/A	($0.07) per share	-0.56
VRAX Virax Biolabs Group	$79.30K	13.33	N/A	N/A	$5.73 per share	0.12

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
SZLSF StageZero Life Sciences	-$11.41M	-$0.12	N/A	∞	N/A	-418.64%	N/A	-1,872.84%	N/A
VRAX Virax Biolabs Group	-$5.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	6/12/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
SZLSF StageZero Life Sciences	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
SZLSF StageZero Life Sciences	N/A	0.04	0.03
VRAX Virax Biolabs Group	N/A	7.59	7.56

Ownership

Institutional Ownership

Company	Institutional Ownership
SZLSF StageZero Life Sciences	N/A
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
SZLSF StageZero Life Sciences	2.54%
VRAX Virax Biolabs Group	45.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
SZLSF StageZero Life Sciences	40	123.53 million	120.40 million	Not Optionable
VRAX Virax Biolabs Group	11	1.56 million	854,000	Not Optionable

SZLSF and VRAX Headlines

Source	Headline
	Virax Biolabs to Participate at ESCMID Global 2024 finance.yahoo.com - April 16 at 9:40 AM
	Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 80.9% in March americanbankingnews.com - April 11 at 3:24 AM
	Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency prnewswire.com - March 15 at 4:30 PM
	Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients finance.yahoo.com - December 21 at 9:32 AM
	Virax Biolabs announces 1-for-10 share consolidation msn.com - December 14 at 12:42 PM
	Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation finance.yahoo.com - December 14 at 7:41 AM
	Virax Biolabs files for up to $30M mixed securities shelf msn.com - December 7 at 12:47 AM
	Virax Biolabs Group Ltd Ord thestreet.com - October 2 at 8:16 AM
	VRAX: Virax Biolabs transformative preventive diagnostic platform supports higher stock price. finance.yahoo.com - September 21 at 7:14 PM
	Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar finance.yahoo.com - September 12 at 10:07 AM
	Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum finance.yahoo.com - September 1 at 12:45 PM
	Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid finance.yahoo.com - August 3 at 8:52 AM
	VRAX: Virax Biolabs releases shareholder letter and financial results for the fiscal year ending March 31, 2023. finance.yahoo.com - June 21 at 6:08 PM
	VRAX: UPDATE: Innovative biotechnology company developing a potentially groundbreaking immunology platform based around proprietary T-Cell testing technology. finance.yahoo.com - May 5 at 3:39 PM
	Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park finance.yahoo.com - May 4 at 8:41 AM
	Virax Biolabs Group Limited Ordinary Shares (VRAX) nasdaq.com - April 21 at 8:05 PM
	Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules finance.yahoo.com - March 10 at 6:45 PM
	Virax Biolabs Group Stock (NASDAQ:VRAX), Dividends benzinga.com - March 8 at 6:52 PM
	Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules finance.yahoo.com - March 8 at 6:52 PM
	Virax Biolabs Stock Soars On Avian Flu Test Kit Agreement: What's Going On? msn.com - March 7 at 5:44 PM
	EXCLUSIVE: Virax Biolabs Starts Distribution Of Avian Flu Test Kits In Europe finance.yahoo.com - March 7 at 5:44 PM
	Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session benzinga.com - March 7 at 1:54 PM
	Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit prnewswire.com - March 7 at 7:35 AM
	VRAX: INITIATION: Innovative biotechnology company developing a potentially groundbreaking immunology platform based around proprietary T-Cell testing technology finance.yahoo.com - February 16 at 1:58 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

StageZero Life Sciences

OTCMKTS:SZLSF

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

Virax Biolabs Group

NASDAQ:VRAX

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial